HDAC inhibitors dissociate the driving complex and reactivate EGR1 and p16INK4a/p14ARF (CDKN2A) expression in synovial sarcoma; we confirm this occurs with treatment by quisinostat, a newer HDAC inhibitor that was the top hit in our compound screen. Here, CDKN2A is linked to synovial sarcoma.